PGP9.5 Recombinant Rabbit monoclonal Antibody IgG
Fig1: Western blot analysis of PGP9.5 on A549 cell lysates using anti-PGP9.5 antibody at 1/1,000 dilution.
Fig2: ICC staining PGP9.5 in N2A cells (red). The nuclear counter stain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS.
Fig3: ICC staining PGP9.5 in PC-12 cells (red). The nuclear counter stain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS.
Host Species; Species ReactivityRabbit; Human, Mouse, Rat
Application SummaryWB, ICC/IF, IHC, IP
Purification; FormulationProA affinity purified; 1*TBS (pH7.4), 1%BSA, 40%Glycerol. Preservative: 0.05% Sodium Azide.; Liquid form.
ALTnamesUbiquitin carboxyl-terminal hydrolase isozyme L1, Neuron cytoplasmic protein 9.5, Ubiquitin thioesterase L1
BackgroundUCH-L1 (ubiquitin C-terminal hydrolase) is a member of a gene family whose products hydrolyze small C-terminal adducts of ubiquitin to generate the ubiquitin monomer. Expression of UCH-L1 is highly specific to neurons and to cells of the diffuse neuroendocrine system and their tumors. UCH-L1 is expressed in brain neurons. Examination of specific brain regions reveals expression in all areas tested, particularly in the substantia nigra. UCH-L1 represents 1-2% of total soluble brain protein. Its occurrence in Lewy bodies and its function in the proteasome pathway make it a compelling candidate gene in Parkinson disease. The gene which encodes UCH-L1 maps to human chromosome 4p13. The 230 amino acid human UCH-L3 protein is 54% identical to that of UCH-L1. UCH-L3 is the predominant thiol protease and has high-affinity binding sites for ubiquitin.(ET1703-22)